YaFarm Technologies, Inc. Announces It Has Signed a Definitive Agreement With The Integrative Stem Cell Institute
February 05 2013 - 9:30AM
Marketwired
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the
Company) is pleased to announce that it has signed a definitive
agreement to acquire the Integrative Stem Cell Institute (the
ISCI). The ISCI is a pioneer in the field of cell-based
regenerative medicine. Combining a world-class medical facility
with a state-of-the-art laboratory, the ISCI provides
investigational treatments to patients as part of clinical studies,
while providing long-term follow up to advance these promising
therapies. The acquisition of the ISCI provides the Company with an
entry into stem cell research and treatment. With the advent of
regenerative medicine, clinics such as the ISCI have taken the
years of scientific research and started to apply them to treatment
of patients.
YaFarm Technologies President Brian Hermenze stated, "Since the
2012 Nobel Prize in Physiology or Medicine was awarded jointly to
John B. Gurdon and Shinya Yamanaka for their work in stem cell
research, we are very excited about the synergies this acquisition
will bring to the Company. The ISCI has been providing
point-of-care therapies to patients for over a year and operates at
an internationally recognized medical facility accredited by both
the Joint Commission and Accreditation Canada International. With a
seasoned and successful management team in place, we believe we are
creating an organization that has the capabilities to understand
and support the many facets of the stem cell industry. We believe
that there will be significant growth opportunities in stem cell
research and treatment in the near future, and it is our intent to
capitalize on them."
Juan Castillo, MD, founder of the ISCI, said, "Physicians from
around the world have shown that cells may have a tremendous impact
on such chronic and debilitating diseases as diabetes, Parkinson's
disease and Chronic Obstructive Pulmonary Disease (COPD)." Dr.
Castillo continued, "The ISCI provides quality patient care and a
uniquely integrated medical community. Our patients, physicians and
researchers work together to provide access to innovative,
point-of-care, cell-based therapies, while evidencing the
regenerative capabilities of cell medicine, and delivering on the
promise of adult stem cell therapies."
In addition, the Company has received final approval from the
Financial Industry Regulatory Authority (FINRA) for a 4 for 1
forward stock split. To receive the dividend the investor must be a
registered shareholder of record on the Company's books on or
before the record date of January 18, 2013. Shareholders who were
not registered as of this date will not receive the dividend.
Shares of YaFarm began trading ex-dividend on January 22, 2013.
YaFarm Technologies currently has 49,857,368 shares issued and
outstanding. Of the issued and outstanding, the current public
float is 17,908,975 and 31,948,393 shares are restricted.
About The Integrative
Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider
of point-of-care, stem cell-based therapies for patients from
around the world. With a state of the art laboratory housed within
the Hospital Galenia in Cancun, Mexico, the ISCI combines the most
advanced scientific application of stem cells with second to none
medical care within the structure of adaptive clinical trials to
effectively track long term outcomes and assure patient safety.
More information on The Integrative Stem Cell Institute is
available on the company's website at http://www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, adequate financing, and
other material risks. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance, or achievements to be materially
different from the statements made herein.
YaFarm Technologies, Inc. Investor Contact: Atlanta Capital
Partners, LLC David Kugelman (866) 692-6847 info@atlcp.com
Profile Solutions (CE) (USOTC:PSIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Profile Solutions (CE) (USOTC:PSIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024